CANCERNA

CANCERNA is an international consortium dedicated to developing RNA-based therapeutics to enhance anti-cancer immune responses. Led by the Hadassah Cancer Research Institute (HCRI) at Hadassah University Medical Center in Jerusalem, Israel, the consortium includes esteemed partners from the pharmaceutical and academic sectors.

The primary objectives of CANCERNA are twofold:

Enhancing Immunogenicity of “Cold” Cancers: These cancers lack genomic mutations and are typically less responsive to immunotherapy. CANCERNA aims to exploit abnormal RNA transcripts to stimulate immune responses against such cancers.

Advancing RNA-Based Immunotherapies: The consortium focuses on developing innovative RNA-based treatments, including personalized mRNA vaccines, to bolster the activity of the immune system against cancer cells.

Supported by the European Union’s Horizon-Health 2021 program, CANCERNA comprises twelve international groups, including pharmaceutical giant Merck KGaA, leading European universities, and renowned research centers. This collaboration underscores the consortium’s commitment to revolutionizing cancer treatment through RNA-based therapies.

For more information about CANCERNA and its innovative work, please visit www.cancerna.info.